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Oncoprotein hides tumor
 
An oncogenic fusion protein hijacks a transcription factor, and uses it to help its tumor avoid 
immune detection, according to a study by Nabarro and colleagues on page 1399. This is the first 
description of an oncoprotein that can both transform cells and shut down the immune response.
The protein, PAX3-FKHR, results from a reciprocal chromosomal translocation in a rare 
form of a childhood muscle cancer, alveolar rhabdomyosarcoma (ARMS). Through the 
combined action of the PAX3 DNA-binding domain and the FKHR transcriptional activation 
domain, the oncoprotein binds and strongly activates PAX3 target genes such as IGF2. This 
activity confers rapid and invasive tumor growth.
Now, this group finds that expression of PAX3-FKHR also significantly dampens immune 
activation, in part by reducing surface levels of class I MHC on transfected cells. A microarray 
screen revealed that expression of the fusion protein repressed numerous genes, 40% of which 
are known targets of STAT1 and/or STAT3, including class I MHC and the cytokine IL-10. Recent 
studies have shown that overactive STAT3 contributes to tumor immune evasion by stifling 
inflammation and preventing crosstalk between innate and adaptive immune systems.
STAT3 also acts as a transcriptional coactivator with FKHR. The group now show that 
PAX3-FKHR also binds to STAT3, but not to STATs 2,4, and 6. Media from cells expressing 
the fusion protein contained at least one inhibitory cytokine, IL-10, and prevented 
dendritic cell (DC) activation. Mouse xenografts expressing PAX3-FKHR had decreased 
inflammatory responses because the numbers of both activated DCs and infiltrating 
neutrophils and macrophages were reduced.
This inhibition of DC activation and immune cell recruitment might help the tumor establish 
an immunoinhibitory environment in which to hide. Determining which target genes help the 
PAX3-FKHRSTAT3 complex to create this environment will require further experiments. 
PAX3-FKHR induction (top) turns on STAT3 
and helps tumors to hide.
 
Double-edged Gadd45
 
On page 1341, Liu and colleagues report that
members of the growth arrest and DNA damage-
inducible (Gadd45) family help both start and
stop effector T cell activity—critically acting to
quench autoimmune T cells gone haywire.
The Gadd45 family is best known and
named for arresting growth of stressed cells by
binding cell cycle machinery. In immune
cells, the Gadd45 proteins directly bind
MEKK4, promoting its activation of the p38 When T cells lack Gadd45 , brains get inflamed.
 
and JNK MAP kinases. Gadd45
 
 
 
 and Gadd45
 
 
 
’s activation
of p38 is essential for jump-starting T helper (Th) type 1
cell differentiation via production of interferon-
 
 
 
 (IFN
 
 
 
).
Previously, this group demonstrated that mice lacking
Gadd45
 
 
 
 mount a much reduced Th1 response against intra-
cellular pathogens like 
 
Listeria monocytogenes
 
. The diminished
IFN
 
 
 
-producing cells suggested that Gadd45
 
 
 
 helps T cells
differentiate. But now their recent studies suggest an additional
function in termination of activated Th1 cells. A balance
between initiation and termination is critical for controlling
Th cell numbers.
Thus, the authors hypothesized that Gadd45
 
 
 
 and
Gadd45
 
 
 
 might control both Th1 initiation and death.
They found that Gadd45
 
 
 
-deficient T cells took a bit
longer to initiate. However, once activated, the cells di-
vided more times and were more resistant to cell death than
 
wild-type T cells.
In a mouse model of multiple sclerosis, experimental
autoimmune encephalomyelitis, Gadd45
 
 
 
 knock-out mice
suffered from a delayed, but prolonged T cell attack on the
brain compared with wild-type mice. This effect was specific
to the Gadd45
 
 
 
-deficient T cells. Mice lacking both
Gadd45
 
 
 
 and Gadd45
 
 
 
 developed spontaneous systemic
autoimmune disorders.
These data suggest that the Gadd45 proteins are re-
quired to initiate an effective Th1 response against certain
pathogens but also to terminate the Th1 response and avoid
autoimmune disease. How the Gadd45 proteins control
both initiation and termination may depend on different
p38 substrates present in naive Th cells versus mature Th1
cells. At this point, says senior author Binfeng Lu, “that’s
pure speculation.” 
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